Target Information

Target General Infomation
Target ID
T30520
Former ID
TTDS00227
Target Name
bacterial RNA polymerase switch region
Target Type
Successful
Disease Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99]
Clostridium difficile associated diarrhea [ICD9: 008.45, 787.91; ICD10: A04.7, A09, K59.1]
Tuberculosis [ICD9: 010-018; ICD10: A15-A19]
Target Validation
T30520
Drugs and Mode of Action
Drug(s) Fidaxomicin Drug Info Approved Clostridium difficile associated diarrhea [531783]
Rifampin Drug Info Approved Tuberculosis [536923]
Rifalazil Drug Info Phase 3 Bacterial infections [521757]
Modulator Fidaxomicin Drug Info [551871]
Inhibitor Rifalazil Drug Info [536472]
Rifampin Drug Info [535323], [536636]
References
Ref 521757ClinicalTrials.gov (NCT00251849) PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients. U.S. National Institutes of Health.
Ref 5317832011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
Ref 536923Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
Ref 535323Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67.
Ref 536472Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
Ref 536636Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. Epub 2008 Feb 22.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.